We exist to improve the lives
of everyone affected by epilepsy

Epilepsy Action update on cannabis-based medicines in the UK

10 Oct 2018

Epilepsy Action senior policy and campaigns officer Sam Mountney provides an update on the current situation with cannabis-based medicines in the UK

"Medicinal cannabis is never far away from the news at the moment. We said we’d follow this issue closely on behalf of the epilepsy community so here’s our take on what’s happened so far and what is happening next.

"In the next few weeks the Home Secretary will begin the process of changing the law in the UK to allow specialist clinicians to prescribe specific cannabis-based medicinal products. This represents an important step towards ensuring people with epilepsy who might benefit from these treatments are able to access them.

"At this stage only specialist clinicians will be able to prescribe cannabis-based medicinal products. Specialist clinicians are expected to keep up to date with new medicines and treatments. Because cannabis in all its forms has been classified as an illegal drug in the UK for over 40 years this change will be complex even for specialist clinicians.

"To support specialist clinicians in making decisions about prescribing cannabis-based medicinal products they will be provided with interim advice and guidance. This will come from a number of organisations including the NHS and the Medicines and Healthcare Regulatory Agency (MHRA).

"Clinical advice will also be provided by professional bodies. While cannabis-based medicines won’t be limited by condition, the interim guidance will focus on three conditions, one of which is severe epilepsy in children. The clinical advice for this will be put together by the British Paediatric Neurological Association (BPNA).

"We are pleased that the government have recognised the potential of cannabis-based medical products to improve the lives of some children with the most severe and treatment resistant epilepsies. We also welcome how quickly the government have acted on this important issue.

"We know that some families have had problems accessing cannabis-based medicinal products through the expert panel set up to review applications. Epilepsy Action share these concerns. When the above changes come in to force, the expert panel will end and decisions will be made directly by specialist clinicians. We hope that this will make access to cannabis-based medical products easier for children who could benefit from them and their families.

"Safety has always been front and centre of our work on cannabis-based medicinal products. However, it is vital that these products are available and accessible to those children who could benefit from them. This is an issue that we will continue to monitor closely.

"We look forward to seeing the advice and guidance from the BPNA and others and will provide a full update when this is published. In the meantime we will continue to represent people with epilepsy in this process and make sure the voices of the epilepsy community are heard."

There are no comments yet. Be the first to comment...

Question about your epilepsy?

Your question will be sent to our helpline advisors.

Have a comment about this page?

All comments are reviewed by a moderator before publishing. Comments will be edited or deleted if they are offensive, libellous, slanderous, abusive, commercial or irrelevant.

We ask for your email when you make a comment through this website. This means that we can let you know directly that we have replied to you. By making a comment through the website, you allow us to use the comment in our publicity without using your name. If we would like to use your name, we will email you to get your permission.

The content of this field is kept private and will not be shown publicly.
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
2 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.